BioNTech

BioNTech SE
TypePublic company
Nasdaq: BNTX
ISINUS09075V1026
IndustryBiotechnology
Founded2008 (2008)
Founders
Headquarters,
Germany
Number of locations
26 (2026)
Area served
Worldwide
Key people
ProductsPfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates
ServicesImmunotherapy
RevenueIncrease €2.87 billion (2025)
Decrease €−1.40 billion (2025)
Decrease €−1.14 billion (2025)
Total assetsDecrease €21.99 billion (2025)
Total equityDecrease €19.22 billion (2025)
Number of employees
Increase 7,807 (2025)
Websitebiontech.com
Footnotes
BioNTech FY 2025 report

BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.

In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.